Investors often compare new drugs to the most effective treatments on efficacy alone. In practice, dermatologists will almost always choose a safer drug with lower efficacy first, creating a huge market for treatments that aren't "best-in-class" but have a superior safety profile.

For a slow-progressing illness like Huntington's, a placebo effect can mask any real drug benefit in a short trial. The strength of the uniQure study is its three-year duration, long enough for the disease's progression to outpace any temporary placebo effect—a nuance the FDA's one-year assessment misses.

The market soured on Nektar's alopecia data because of low overall response rates. This misses that the drug is slow-acting and nearly half the patients dropped out before it could take effect. The real efficacy is likely much higher among patients who complete the full treatment course.

Apogee positions its 3- and 6-month dosing as a driver of superior adherence and better long-term outcomes, not just a lifestyle perk. The CEO draws a parallel to the psoriasis market, where less frequent dosing transformed the therapeutic landscape by encouraging more patients to start and stay on therapy.

Unlike conditions with transient flare-ups, missing a few doses of a fast-acting alopecia drug can cause catastrophic hair loss, erasing years of progress. A long-acting injectable provides a crucial buffer against real-world issues like insurance delays, making it a uniquely superior option for patients despite the injection route.

Instead of targeting new biological pathways, Apogee enhances proven antibody therapies by extending their half-life. This shifts the competitive battleground from pure scientific discovery to patient adherence and lifestyle, aiming for quarterly or semi-annual dosing versus the current bi-weekly standard for market leaders.

Unlike typical autoimmune drugs that block or suppress the immune system, Nektar's ResPeg works by increasing anti-inflammatory cells. This mechanism allows for a marketing narrative centered on "restoring balance" rather than "inhibition," which can be more appealing and reassuring to patients wary of suppressing their immune system.

For RNAi and antisense therapies targeting chronic conditions like cardiovascular disease, the critical competitive advantage is durability, not just efficacy. The ability to offer infrequent dosing, such as twice-yearly injections, represents a significant step-change from daily medications and is the key factor expected to drive market adoption.

In rare NRG1-fusion positive cancers, targeted therapy shows a modest 29% objective response rate, below the typical 40% benchmark for accelerated approval. However, the median duration of response is nearly a year (and 1.5 years in naive patients), making it a highly effective, life-altering therapy for responders. This highlights duration, not just rate, as a key efficacy metric.